A patient developed a rare and fatal form of blood cancer just one month after receiving chimeric antigen receptor (CAR) T-cell therapy, according to a recent case study published in the New England Journal of Medicine.
The authors wrote that CAR T-cell therapy, which treats cancer by modifying the genes of a patient’s immune cells, did not cause the T-cell lymphoma.
